Isopto (Pilocarpine Hydrochloride)

Pilocarpine hydrochloride acts as a direct agonist at muscarinic receptors in the eye. Stimulation of these receptors contracts the sphincter pupillae and ciliary muscles, opening the trabecular meshwork and enhancing aqueous humor outflow, which reduces intra‑ocular pressure.

The exact dosing regimen for Isopto is determined by the prescribing clinician based on the individual patient's condition, response, and tolerance. Typically, the prescriber will specify the number of drops and frequency appropriate for the therapeutic goal.

Safety data for pilocarpine hydrochloride during pregnancy and lactation are limited. The product is classified as pregnancy category unknown, so clinicians must weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing patients.

To request Isopto, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to pilocarpine is a beta‑blocker such as timolol, which lowers intra‑ocular pressure by reducing aqueous humor production. Pilocarpine increases outflow, while beta‑blockers decrease production. Choice depends on patient tolerance, contraindications, and desired mechanism of action.

Isopto should be stored at room temperature, below 25 °C, in its original container. Protect the solution from light, moisture and extreme temperatures. Keep the bottle tightly closed when not in use and discard any product that appears discolored or contaminated.

Isopto is applied topically to the eye. The patient places the prescribed number of drops into the conjunctival sac of the affected eye(s), typically without touching the tip of the bottle to the eye or surrounding tissues, and follows any specific timing instructions from the prescriber.

Serious risks include severe allergic reactions such as swelling, rash or breathing difficulty, and the rare occurrence of acute angle‑closure glaucoma, which can cause sudden eye pain and vision loss. Prompt medical attention is required if these symptoms develop.

Isopto should not be used by individuals with known hypersensitivity to pilocarpine or any formulation components, patients with narrow‑angle glaucoma, or those with active severe ocular inflammation. Clinicians should also avoid use in patients where the risk of excessive miosis outweighs therapeutic benefit.